open access

Vol 15, No 1 (2008)
Original articles
Published online: 2007-12-17
Get Citation

The influence of permanent cardiac pacing on plasma levels of B-type natriuretic peptide in patients with sick sinus syndrome

Marcin Sadowski, Beata Wożakowska-Kapłon
Cardiol J 2008;15(1):39-42.

open access

Vol 15, No 1 (2008)
Original articles
Published online: 2007-12-17

Abstract

Background: Unequivocal data presenting the impact of different pacing modes on B-type natriuretic peptide levels has never been published. The aim of the study was to assess changes of plasma B-type natriuretic peptide (BNP) during permanent cardiac pacing in patients with sick sinus syndrome (SSS).
Methods: Patients with SSS undergoing routine pacemaker implantation were enrolled. Each subject underwent medical history and examination, echocardiography and blood sampling. Analysis was performed on 12 females (42.9%) and 16 males (57.1%), mean age 71.3 ± 9.03 years, range 49-90 years. There were 11 pacemakers with AAIR pacing mode (39.3%; AAI group) and 17 with DDDR mode (60.7%; DDD group) implanted. There were no significant differences in age, concomitant diseases or echocardiographic parameters between the groups in baseline characteristics or plasma BNP levels (94.05 ± 54.1 vs. 73.57 ± 70.13 pg/mL; p > 0.2).
Results: During six months follow-up no significant changes in plasma BNP levels in AAI group (94.05 ± 54.1 vs. 94.05 ± 54.1 pg/mL; p > 0.5) as well as in DDD group (73.57 ± 70.1 vs. 82.39 ± 58.9 pg/mL; p > 0.5) were noticed.
Conclusions: Atrial (AAIR) and dual chamber (DDDR) pacing did not influence plasma BNP levels in patients with SSS and preserved left ventricular systolic function. (Cardiol J 2008; 15: 39-42)

Abstract

Background: Unequivocal data presenting the impact of different pacing modes on B-type natriuretic peptide levels has never been published. The aim of the study was to assess changes of plasma B-type natriuretic peptide (BNP) during permanent cardiac pacing in patients with sick sinus syndrome (SSS).
Methods: Patients with SSS undergoing routine pacemaker implantation were enrolled. Each subject underwent medical history and examination, echocardiography and blood sampling. Analysis was performed on 12 females (42.9%) and 16 males (57.1%), mean age 71.3 ± 9.03 years, range 49-90 years. There were 11 pacemakers with AAIR pacing mode (39.3%; AAI group) and 17 with DDDR mode (60.7%; DDD group) implanted. There were no significant differences in age, concomitant diseases or echocardiographic parameters between the groups in baseline characteristics or plasma BNP levels (94.05 ± 54.1 vs. 73.57 ± 70.13 pg/mL; p > 0.2).
Results: During six months follow-up no significant changes in plasma BNP levels in AAI group (94.05 ± 54.1 vs. 94.05 ± 54.1 pg/mL; p > 0.5) as well as in DDD group (73.57 ± 70.1 vs. 82.39 ± 58.9 pg/mL; p > 0.5) were noticed.
Conclusions: Atrial (AAIR) and dual chamber (DDDR) pacing did not influence plasma BNP levels in patients with SSS and preserved left ventricular systolic function. (Cardiol J 2008; 15: 39-42)
Get Citation

Keywords

sick sinus syndrome; BNP; permanent cardiac pacing

About this article
Title

The influence of permanent cardiac pacing on plasma levels of B-type natriuretic peptide in patients with sick sinus syndrome

Journal

Cardiology Journal

Issue

Vol 15, No 1 (2008)

Pages

39-42

Published online

2007-12-17

Bibliographic record

Cardiol J 2008;15(1):39-42.

Keywords

sick sinus syndrome
BNP
permanent cardiac pacing

Authors

Marcin Sadowski
Beata Wożakowska-Kapłon

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl